Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Neuphoria Therapeutics In...

    NASDAQ: NEUP · Real-Time Price · USD
    6.84
    -0.31 (-4.34%)
    At close: Jun 06, 2025, 3:45 PM
    6.82
    -0.37%
    After-hours: Jun 06, 2025, 05:51 PM EDT

    Neuphoria Therapeutics Statistics

    Share Statistics

    Neuphoria Therapeutics has 1.88M shares outstanding. The number of shares has increased by null% in one year.

    Shares Outstanding

    n/a
    		 1.88M

    Shares Change (YoY)

    n/a
    		 n/a

    Shares Change (QoQ)

    n/a
    		 n/a

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 156

    FTD / Avg. Volume

    n/a
    		 0.52%

    Short Selling Information

    The latest short interest is 20.31K, so 1.08% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 20.31K

    Short % of Shares Out

    n/a
    		 1.08%

    Short % of Float

    n/a
    		 1.08%

    Short Ratio (days to cover)

    n/a
    		 1.96

    Valuation Ratios

    The PE ratio is -80.06 and the forward PE ratio is -1.05. Neuphoria Therapeutics's PEG ratio is 1.94.

    PE Ratio

    n/a
    		 -80.06

    Forward PE

    n/a
    		 -1.05

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.2

    PB Ratio

    n/a
    		 70.92

    P/FCF Ratio

    n/a
    		 -84.49

    PEG Ratio

    n/a
    		 1.94
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Neuphoria Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.45, with a Debt / Equity ratio of 0.02.

    Current Ratio

    n/a
    		 3.45

    Quick Ratio

    n/a
    		 3.45

    Debt / Equity

    n/a
    		 0.02

    Debt / EBITDA

    n/a
    		 -0.02

    Debt / FCF

    n/a
    		 -0.02

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,936,520.75

    Employee Count

    n/a
    		 8

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -87.32K

    Effective Tax Rate

    n/a
    		 0.56%

    Stock Price Statistics

    The stock price has increased by -18.7% in the last 52 weeks. The beta is 0.46, so Neuphoria Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.46

    52-Week Price Change

    n/a
    		 -18.7%

    50-Day Moving Average

    n/a
    		 5.48

    200-Day Moving Average

    n/a
    		 4.93

    Relative Strength Index (RSI)

    n/a
    		 74.01

    Average Volume (20 Days)

    n/a
    		 30,222

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -17.89M

    Net Income

    n/a
    		 -15.49M

    EBITDA

    n/a
    		 -17.13M

    EBIT

    n/a
    		 -17.8M

    Earnings Per Share (EPS)

    n/a
    		 -0.1
    Full Income Statement

    Balance Sheet

    The company has 12.61M in cash and 272.74K in debt, giving a net cash position of 12.34M.

    Cash & Cash Equivalents

    n/a
    		 12.61M

    Total Debt

    n/a
    		 272.74K

    Net Cash

    n/a
    		 12.34M

    Retained Earnings

    n/a
    		 -177.98M

    Total Assets

    n/a
    		 30.71M

    Working Capital

    n/a
    		 15.54M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -14.68M and capital expenditures 0, giving a free cash flow of -14.68M.

    Operating Cash Flow

    n/a
    		 -14.68M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -14.68M

    FCF Per Share

    n/a
    		 -0.1
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    NEUP does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for NEUP is $21, which is 194.5% higher than the current price. The consensus rating is "Strong Buy".

    Price Target

    n/a
    		 $21

    Price Target Difference

    n/a
    		 194.5%

    Analyst Consensus

    n/a
    		 Strong Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Dec 24, 2024. It was a backward split with a ratio of 1:12.

    Last Split Date

    n/a
    		 Dec 24, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:12

    Scores

    Altman Z-Score

    n/a
    		 -4.5

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist